8.17
8.17 (0%)
As of Apr 17, 2025
Dyne Therapeutics, Inc. [DYN]
Source:
Company Overview
Dyne Therapeutics, Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | (781) 786-8230 |
| Industry | |
| CEO | Joshua Brumm |
| Website | www.dyne-tx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-343.9 |
| Net Income | $-317.4 |
| Net Cash | $313.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -74.1% |
| Profit as % of Stockholder Equity | -50.4% |
Management Effectiveness
| Return on Equity | -50.4% |
| Return on Assets | -45.9% |
| Turnover Ratio | |
| EBITA | $-343.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $691.2 |
| Total Liabilities | $61.4 |
| Operating Cash Flow | $-292.4 |
| Investing Cash Flow | $-204.1 |
| Financing Cash Flow | $809.9 |
